Drug Type Bispecific antibody |
Synonyms PM 1009, PM1009 |
Target |
Mechanism CD112R antagonists(Transmembrane protein PVRIG antagonists), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic hepatocellular carcinoma | Phase 2 | - | 01 Dec 2024 | |
Hepatocellular Carcinoma | Phase 2 | CN | 30 Aug 2024 | |
Advanced cancer | Phase 1 | CN | 17 Nov 2022 | |
Locally Advanced Hepatocellular Carcinoma | IND Approval | CN | 10 Jul 2024 | |
Lung Cancer | IND Approval | CN | 20 Sep 2022 |
Phase 1 | 12 | cdugmosqbe(jyuslkbnud) = qfjjzwfirp lvcdbexioi (dyqlmxbpgq, 9.92 - 65.11) View more | Positive | 24 May 2024 | |||
cdugmosqbe(jyuslkbnud) = wpqnaribmx lvcdbexioi (dyqlmxbpgq, 9.92 - 65.11) View more |